Co-Diagnostics and CoSara to Launch IVD Products to India MarketHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Co-Diagnostics and CoSara to Launch IVD Products to India MarketGlobeNewswireJanuary 2, 2020ReblogShareTweetShareCoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic ExpoSalt Lake City, Jan. 01, 2020 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming India Diagnostic Expo with its Indian joint venture, CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), on January 4-6 in Hyderabad, India, to formally launch their recently-approved in vitro diagnostics (IVDs).The India Diagnostic Expo provides India’s only focused diagnostics products and consumables exhibition for the diagnostic services market, which is expected to continue growing at 27.5% for the next 5 years. Attendance at the expo follows the December 2019 announcement that CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV) received IVD approval by the Central Drug Standard Control Organization (“CDSCO”). The licenses and regulatory clearance granted by the CDSCO allow the 5 tests to be manufactured and sold for the detection of the respective diseases, with the expo marking their first formal launch to the Indian market.The Company and CoSara invite attendees to visit them at Booth #C-108 daily from 10 AM to 6 PM at the Hitex Exhibition Center, Venue Hall 3.Dwight Egan, CEO of Co-Diagnostics, commented “We are pleased to officially launch these newly-approved diagnostics tests into India. We believe that our patented technology and proprietary design process gives products designed on the CoPrimer™ platform a competitive edge in such a large and growing market, and the Company looks forward to a successful roll-out of these in-demand diagnostics.”About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.Forward-Looking Statements:This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release may include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in certain verticals or markets, (iv) capital resources and runway needed to advance the Company’s products and markets, (v) increased sales in the near-term, (vi) flexibility in managing the Company’s balance sheet, (vii) anticipation of business expansion, and (vii) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Company Contact:                                                                         Andrew Benson                   Head of Investor Relations                                                               +1 801-438-1036                                                                                a.benson@codiagnostics.comStory continuesReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextConfidence returning for UK consumers and companies - surveysReutersTrump campaign ads target a new audience: Indian AmericansPoliticoUS urges India to allow peaceful assembly after riotsAFPA Delhi neighborhood divided by a highway and now hatredReutersRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDoorDash Files Confidentially for IPOThe Wall Street JournalDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoA Rumored Gilead Takeover Offer Sent This Biotech Stock FlyingInvestor's Business Daily